Data quality and methodology in studies on maternal medication use in relation to congenital anomalies

Linda de Jonge

Data quality and methodology in studies on maternal medication use in relation to congenital anomalies

Linda de Jonge

Onderzoeksoutput

796 Downloads (Pure)

Samenvatting

In Nederland wordt ongeveer 1 op de 30 kinderen geboren met een aangeboren afwijking, zoals een open ruggetje (spina bifida), gespleten lip en/of gehemelte (schisis), of een gaatje in het hart (septum defect). Eén van de risicofactoren voor het ontstaan van een aangeboren afwijking is medicijngebruik door de moeder tijdens de zwangerschap. Veel vrouwen gebruiken medicijnen gedurende hun zwangerschap, terwijl van verschillende geneesmiddelen niet helemaal duidelijk is of deze mogelijk schadelijk kunnen zijn voor het ongeboren kind. Om onderzoek te doen naar mogelijke relaties tussen medicijngebruik van de moeder tijdens de zwangerschap en aangeboren afwijkingen, zijn speciale databases nodig met zo volledig mogelijke informatie over aangeboren afwijkingen, zoals de EUROCAT database. EUROCAT is een Europees netwerk van registraties van kinderen met aangeboren afwijkingen. Daarnaast is goede informatie over medicijngebruik tijdens de zwangerschap nodig.
Uit dit promotieonderzoek is gebleken dat het koppelen van databases met gegevens over voorgeschreven medicijnen aan de EUROCAT-data van grote toegevoegde waarde is, omdat de EUROCAT-data voor wat betreft bepaalde medicatie, zoals antidepressiva, anti-astmamedicatie, antibiotica en bepaalde ovulatie-stimulerende middelen niet compleet zijn. Omdat het onduidelijk is of de medicijnen die tijdens de zwangerschap zijn voorgeschreven ook daadwerkelijk zijn gebruikt, hebben we ook hier onderzoek naar verricht. Voor de meeste geneesmiddelgroepen bleek dit wel het geval, waardoor we kunnen stellen dat voorschrijfgegevens gebruikt kunnen worden als een betrouwbare bron voor het onderzoek naar medicijngebruik tijdens de zwangerschap. Voor het goed kunnen monitoren van medicijngebruik tijdens de zwangerschap in relatie tot aangeboren afwijkingen bij het kind, zijn grote databases nodig die alleen gerealiseerd kunnen worden door internationale samenwerking, zoals in het EUROmediCAT project.

Originele taal-2	English
Kwalificatie	Doctor of Philosophy
Toekennende instantie	Rijksuniversiteit Groningen
Begeleider(s)/adviseur	van Langen, Irene, Supervisor van den Berg, Lolkje, Supervisor Bakker, Marian, Co-supervisor
Datum van toekenning	2-mrt.-2016
Plaats van publicatie	[Groningen]
Uitgever	Rijksuniversiteit Groningen
Gedrukte ISBN's	978-90-367-8622-5
Elektronische ISBN's	978-90-367-8621-8
Status	Published - 2016

Toegang tot document

Complete thesisFinal publisher's version, 3,81 MB
PropositionsFinal publisher's version, 385 KB

Handle.net

Permanente koppeling

EUROCAT Northern Netherlands
Broekstra, D. (Supervisor), Kammen-Bergman, van, J. (Contributor), Bakker, M. (Contributor), Lutke, L. (Contributor), Doornbos, F. (Contributor), Smeijer-Ramocha, L. (Data Manager), van der Woude, A. (Contributor), de Walle, H. (Contributor) & Muhlenberg, N. (Data Manager), University of Groningen, 1981
DOI: 10.34760/5f5b80ff2a7a4, http://eurocat.umcg.nl
Dataset

Citeer dit

@phdthesis{845a63d82f4c483b820bf5ae3c28d822,

title = "Data quality and methodology in studies on maternal medication use in relation to congenital anomalies",

abstract = "In the Netherlands one in 30 children is born with a congenital anomaly, like spina bifida, cleft or a heart defect. One of the risk factors for congenital anomalies is maternal medication taken during pregnancy; this is very common, despite uncertainties about the safety of many medicines. Special databases to record full information on congenital anomalies are needed to be able to investigate possible associations with maternal medication use during pregnancy. EUROCAT maintains one such database. EUROCAT is an European network of congenital anomalies registries. In addition, good information on maternal medication use during pregnancy is needed.This thesis shows that linking prescription databases to EUROCAT data supplements the data recorded on mother{\textquoteright}s medication use, which is not always complete for specific medications like certain antidepressants, anti-asthmatics, antibacterials, and some ovulation stimulants. However, from prescription databases it is still unclear whether the prescribed medication was actually taken. We therefore studied the actual use of medicines during pregnancy. It seems that most medication is indeed taken, which means that data from prescription records can be used as a reliable source of data for research into medication use during pregnancy. Very large databases are needed for monitoring possible associations between maternal medication use in pregnancy and congenital anomalies and these can only be realised by international collaborations, as formed for the EUROmediCAT project, for example.",

author = "{de Jonge}, Linda",

year = "2016",

language = "English",

isbn = "978-90-367-8622-5",

publisher = "Rijksuniversiteit Groningen",

school = "University of Groningen",

}

TY - BOOK

T1 - Data quality and methodology in studies on maternal medication use in relation to congenital anomalies

AU - de Jonge, Linda

PY - 2016

Y1 - 2016

N2 - In the Netherlands one in 30 children is born with a congenital anomaly, like spina bifida, cleft or a heart defect. One of the risk factors for congenital anomalies is maternal medication taken during pregnancy; this is very common, despite uncertainties about the safety of many medicines. Special databases to record full information on congenital anomalies are needed to be able to investigate possible associations with maternal medication use during pregnancy. EUROCAT maintains one such database. EUROCAT is an European network of congenital anomalies registries. In addition, good information on maternal medication use during pregnancy is needed.This thesis shows that linking prescription databases to EUROCAT data supplements the data recorded on mother’s medication use, which is not always complete for specific medications like certain antidepressants, anti-asthmatics, antibacterials, and some ovulation stimulants. However, from prescription databases it is still unclear whether the prescribed medication was actually taken. We therefore studied the actual use of medicines during pregnancy. It seems that most medication is indeed taken, which means that data from prescription records can be used as a reliable source of data for research into medication use during pregnancy. Very large databases are needed for monitoring possible associations between maternal medication use in pregnancy and congenital anomalies and these can only be realised by international collaborations, as formed for the EUROmediCAT project, for example.

AB - In the Netherlands one in 30 children is born with a congenital anomaly, like spina bifida, cleft or a heart defect. One of the risk factors for congenital anomalies is maternal medication taken during pregnancy; this is very common, despite uncertainties about the safety of many medicines. Special databases to record full information on congenital anomalies are needed to be able to investigate possible associations with maternal medication use during pregnancy. EUROCAT maintains one such database. EUROCAT is an European network of congenital anomalies registries. In addition, good information on maternal medication use during pregnancy is needed.This thesis shows that linking prescription databases to EUROCAT data supplements the data recorded on mother’s medication use, which is not always complete for specific medications like certain antidepressants, anti-asthmatics, antibacterials, and some ovulation stimulants. However, from prescription databases it is still unclear whether the prescribed medication was actually taken. We therefore studied the actual use of medicines during pregnancy. It seems that most medication is indeed taken, which means that data from prescription records can be used as a reliable source of data for research into medication use during pregnancy. Very large databases are needed for monitoring possible associations between maternal medication use in pregnancy and congenital anomalies and these can only be realised by international collaborations, as formed for the EUROmediCAT project, for example.

M3 - Thesis fully internal (DIV)

SN - 978-90-367-8622-5

PB - Rijksuniversiteit Groningen

CY - [Groningen]

ER -

Data quality and methodology in studies on maternal medication use in relation to congenital anomalies

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Datasets

EUROCAT Northern Netherlands

Citeer dit